At 6.6% CAGR, the North America Diabetic Foot Ulcer Market is projected to be worth US$ 5,943.56 million by 2030, says Business Market Insights.

According to Business Market Insights' research, the North America diabetic foot ulcer market was valued at US$ 3,570.76 in 2022 and is expected to reach US$ 5,943.56 million by 2030, registering a CAGR of 6.6% from 2022 to 2030. High prevalence of diabetes and related chronic wounds is among the critical factors attributed to the North America diabetic foot ulcer market expansion.

Diabetic patients are vulnerable to wounds, and the healing process is usually longer. Depending on healing timeframe, wounds are classified as acute and chronic. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes can lead to various complications in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF), in 2021, there were ∼537 million adults living with diabetes worldwide. The number is anticipated to increase to 643 million by 2030 and 783 million by 2045. Blood vessels and nerves in the feet of diabetic patients are prone to damages, resulting in numbness. Due to this, diabetic patients have a higher chance of developing diabetic foot ulceration. According to a study published in 2021 in National Center for Biotechnology Information (NCBI), the risk of developing diabetic foot ulcers is between 19% and 34%. Approximately, a recurrence rate of 40% is experienced by patients within 1 year of recovery, 60% within 3 years, and 65% within 5 years. As per same study, it is reported that infection develops in 50–60% of ulcers and is the principal cause that damages diabetic feet. Thus, the demand for diabetic foot ulcer treatments is on rise globally, thereby fueling the market growth.

On the contrary, high cost of advanced wound care treatments hampers the growth North America diabetic foot ulcer market.

Based on treatment type, the North America diabetic foot ulcer market is segmented into advanced wound care dressings, therapy device, and biologics. The advanced wound care dressings segment held 54.6% share of the North America diabetic foot ulcer market in 2022, amassing US$ 1,948.60 million. It is projected to garner US$ 3,301.93 million by 2030 to expand at 6.8% CAGR during 2022-2030.

Based on ulcer type, the North America diabetic foot ulcer market is segmented into neuro-lschemic ulcers, neuropathic ulcers, and ischemic ulcers. The neuro-lschemic ulcers segment held 50.6% share of the North America diabetic foot ulcer market in 2022, amassing US$ 1,808.24 million. It is projected to garner US$ 3,083.57 million by 2030 to expand at 6.9% CAGR during 2022–2030.

Based on infection severity, the North America diabetic foot ulcer market is segmented into mild, moderate, and severe. The mild segment held 47.3% share of North America diabetic foot ulcer market in 2022, amassing US$ 1,689.89 million. It is projected to garner US$ 2,902.59 million by 2030 to expand at 7.0% CAGR during 2022–2030.

Based on end user, the North America diabetic foot ulcer market is segmented into hospitals, ambulatory surgical centers, and home care. The hospitals segment held 56.9% share of North America diabetic foot ulcer market in 2022, amassing US$ 2,032.45 million. It is projected to garner US$ 3,504.99 million by 2030 to expand at 7.0% CAGR during 2022–2030.

Based on country, the North America diabetic foot ulcer market is segmented into US, Canada, and Mexico. The US held 85.4% share of North America diabetic foot ulcer market in 2022, amassing US$ 3,049.79 million. It is projected to garner US$ 5,122.75 million by 2030 to expand at 6.7% CAGR during 2022–2030.

Key players operating in the North America diabetic foot ulcer market are Convatec Group Plc, 3M Co, Coloplast AS, Smith & Nephew Plc, B. Braun SE, Medline Industries LP, Organogenesis Inc., Mölnlycke Health Care AB, and MiMedx Group Inc, among others.

• In Jul 2022, Smith+Nephew announced the launch of the WOUND COMPASS Clinical Support App. It is a comprehensive digital support tool for healthcare professionals that aids wound assessment and decision-making to help reduce practice variation. The App helps improve nurse confidence when assessing and treating wounds and reassuring specialist nurses that their formulary is followed.
• In Jul 2023, MiMedx Group, Inc. announced a strategic realignment designed to focus the Company’s resources on accelerating its Wound & Surgical business growth, driving profitability, and enhancing cash flow generation.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com